• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    11/7/24 4:17:05 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OTLK alert in real time by email
    SC 13G/A 1 sc13ga112927033_11072024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    Outlook Therapeutics, Inc.

     (Name of Issuer)

    Common Stock, par value $0.01 per share

     (Title of Class of Securities)

    69012T305

     (CUSIP Number)

    September 30, 2024

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 69012T305

     

      1   NAME OF REPORTING PERSON  
             
            Velan Capital Master Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         750,000*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              750,000*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            750,000*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.1%*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    * Consists of 750,000 Shares issuable upon the exercise of certain warrants (the “Warrants”).

    2

    CUSIP No. 69012T305

      1   NAME OF REPORTING PERSON  
             
            Velan Capital Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         750,000*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              750,000*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            750,000*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.1%*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Consists of 750,000 Shares issuable upon the exercise of the Warrants.

    3

    CUSIP No. 69012T305

     

      1   NAME OF REPORTING PERSON  
             
            Velan Capital Investment Management LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         750,000*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              750,000*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            750,000*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.1%*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    * Consists of 750,000 Shares issuable upon the exercise of the Warrants.

    4

    CUSIP No. 69012T305

     

      1   NAME OF REPORTING PERSON  
             
            Velan Capital Management LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         750,000*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              750,000*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            750,000*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.1%*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Consists of 750,000 Shares issuable upon the exercise of the Warrants.

    5

    CUSIP No. 69012T305

     

      1   NAME OF REPORTING PERSON  
             
            Adam Morgan  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         750,000*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              750,000*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            750,000*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.1%*  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    * Consists of 750,000 Shares issuable upon the exercise of the Warrants.

    6

    CUSIP No. 69012T305

     

      1   NAME OF REPORTING PERSON  
             
            Balaji Venkataraman  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         750,000*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              750,000*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            750,000*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.1%*  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    * Consists of 750,000 Shares issuable upon the exercise of the Warrants.

    7

    CUSIP No. 69012T305

    Item 1(a).Name of Issuer:

     

    Outlook Therapeutics, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    485 Route 1 South

    Building F, Suite 320

    Iselin, New Jersey 08830

     

    Item 2(a).Name of Person Filing:

     

    This statement is filed by:

     

    (i)Velan Capital Master Fund LP, an exempted limited partnership organized under the laws of the Cayman Islands (“Velan Master”), with respect to the Shares (as defined below) directly and beneficially owned by it;
    (ii)Velan Capital Holdings LLC, a Delaware limited liability company (“Velan GP”), as the general partner of Velan Master;
    (iii)Velan Capital Investment Management LP, a Delaware limited partnership (“Velan Capital”), as the investment manager of Velan Master;
    (iv)Velan Capital Management LLC, a Delaware limited liability company (“Velan IM GP”), as the general partner of Velan Capital;
    (v)Adam Morgan, as a Managing Member of each of Velan GP and Velan IM GP; and
    (vi)Balaji Venkataraman, as a Managing Member of each of Velan GP and Velan IM GP.

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal office of Velan Master is 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands. The address of the principal office of each of Velan GP, Velan Capital, Velan IM GP and Messrs. Morgan and Venkataraman is 100 North Main Street, Suite 301, Alpharetta, Georgia 30009.

     

    Item 2(c).Citizenship:

     

    (i)Velan Master – Cayman Islands
    (ii)Velan GP – Delaware
    (iii)Velan Capital – Delaware
    (iv)Velan IM GP – Delaware
    (v)Mr. Morgan – United States of America
    (vi)Mr. Venkataraman – United States of America

     

    8

    CUSIP No. 69012T305

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.01 per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    69012T305

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    As of the close of business on September 30, 2024:

     

    i.Velan Master directly beneficially owned 750,000 Shares, consisting of 750,000 Shares issuable upon the exercise of the Warrants;
    ii.Velan GP, as the general partner of Velan Master, may be deemed to beneficially own the 750,000 Shares beneficially owned directly by Velan Master;
    9

    CUSIP No. 69012T305

    iii.Velan Capital, as the investment manager of Velan Master, may be deemed to beneficially own the 750,000 Shares beneficially owned directly by Velan Master;
    iv.Velan IM GP, as the general partner of Velan Capital, may be deemed to beneficially own the 750,000 Shares beneficially owned directly by Velan Master;
    v.Mr. Morgan, as a Managing Member of each of Velan GP and Velan IM GP, may be deemed to beneficially own the 750,000 Shares beneficially owned directly by Velan Master; and
    vi.Mr. Venkataraman, as a Managing Member of each of Velan GP and Velan IM GP, may be deemed to beneficially own the 750,000 Shares beneficially owned directly by Velan Master.

     

    The filing of this Schedule 13G shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

     

    (b)Percent of class:

     

    The following percentages are based on 23,655,636 Shares outstanding as of August 12, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2024, plus the Shares underlying the Warrants that may be exercised by the Reporting Persons.

     

    As of the close of business on September 30, 2024, (i) Velan Master beneficially owns approximately 3.1% of the outstanding Shares, (ii) Velan GP may be deemed to beneficially own approximately 3.1% of the outstanding Shares, (iii) Velan Capital may be deemed to beneficially own approximately 3.1% of the outstanding Shares, (iv) Velan IM GP may be deemed to beneficially own approximately 3.1% of the outstanding Shares, (v) Mr. Morgan may be deemed to beneficially own approximately 3.1% of the outstanding Shares and (vi) Mr. Venkataraman may be deemed to beneficially own approximately 3.1% of the outstanding Shares.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

     

    10

    CUSIP No. 69012T305

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1 to the Schedule 13G filed on March 28, 2024.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    11

    CUSIP No. 69012T305

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 7, 2024

     

      Velan Capital Master Fund LP
       
      By: Velan Capital Holdings LLC
    General Partner
       
      By:

    /s/ Adam Morgan

        Name: Adam Morgan
        Title: Managing Member

     

     

      Velan Capital Holdings LLC
         
      By:

    /s/ Adam Morgan

        Name: Adam Morgan
        Title: Managing Member

     

     

      Velan Capital Investment Management LP
       
      By: Velan Capital Management LLC
    General Partner
       
      By:

    /s/ Adam Morgan

        Name: Adam Morgan
        Title: Managing Member

     

     

      Velan Capital Management LLC
       
      By:

    /s/ Adam Morgan

        Name: Adam Morgan
        Title: Managing Member

     

     

     

    /s/ Adam Morgan

      Adam Morgan

     

     

     

    /s/ Balaji Venkataraman

      Balaji Venkataraman

    12

     

    Get the next $OTLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTLK

    DatePrice TargetRatingAnalyst
    12/2/2024Buy → Neutral
    Chardan Capital Markets
    3/27/2024$50.00Neutral → Buy
    BTIG Research
    2/15/2024$3.00Neutral → Buy
    Chardan Capital Markets
    1/25/2024Neutral → Buy
    Guggenheim
    12/27/2023$5.00Equal Weight → Overweight
    CapitalOne
    8/31/2023$5.00 → $1.00Buy → Neutral
    H.C. Wainwright
    8/31/2023Buy → Neutral
    Chardan Capital Markets
    8/30/2023Overweight → Equal Weight
    CapitalOne
    More analyst ratings

    $OTLK
    Leadership Updates

    Live Leadership Updates

    See more
    • Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

      ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will remain on the Board as Lead Independent Director. "On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest

      1/31/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Announces Executive Leadership Transition

      ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company's President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. "On behalf of our management team

      12/3/24 4:30:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe

      ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the appointment of Jedd Comiskey as Senior VP – Head of Europe. Mr. Comiskey has a successful track record in the planning, organization and execution of product launches. Over the course of his career, he has demonstrated innovative, solution-focused results, navigating the highly complex European pharmaceutical landscape. "We believe in the potential of ONS-5010 to address the global need for an approved bevacizumab that meets ophtha

      11/14/23 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    SEC Filings

    See more
    • SEC Form 424B5 filed by Outlook Therapeutics Inc.

      424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)

      5/23/25 4:36:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

      5/23/25 4:22:38 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Outlook Therapeutics Inc.

      424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)

      5/22/25 4:26:40 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Financials

    Live finance-specific insights

    See more
    • Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

      LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz

      5/15/25 4:01:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

      ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025 ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a co

      2/14/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

      LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for fisca

      12/27/24 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Outlook Therapeutics downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Outlook Therapeutics from Buy to Neutral

      12/2/24 10:06:30 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics upgraded by BTIG Research with a new price target

      BTIG Research upgraded Outlook Therapeutics from Neutral to Buy and set a new price target of $50.00

      3/27/24 7:31:34 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Outlook Therapeutics from Neutral to Buy and set a new price target of $3.00

      2/15/24 7:17:37 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Kenyon Lawrence A bought $28,446 worth of shares (5,000 units at $5.69), increasing direct ownership by 529% to 5,946 units (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      9/30/24 4:53:23 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Syntone Ventures Llc bought 714,286 shares, increasing direct ownership by 72% to 1,705,438 units (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      4/17/24 8:21:17 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Haddadin Yezan Munther bought $22,242 worth of shares (1,882 units at $11.82), increasing direct ownership by 59% to 5,049 units (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      3/29/24 10:39:09 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

      SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

      11/14/24 4:55:26 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

      SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

      11/7/24 4:17:05 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Outlook Therapeutics Inc. (Amendment)

      SC 13D/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

      4/17/24 9:38:26 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

      ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares of its common stock, together with accompanying warrants to purchase 18,571,428 shares of its common stock. The combined public offering price of common stock and accompanying warrant is $1.40. The common stock is being sold in combination with an accompanying warrant to purchase two shares of common stock issued for each share of common stock sold. The accompanying warrant has an exercise price of

      5/23/25 6:30:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

      ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general corporate purposes. BTIG

      5/22/25 4:01:03 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

      LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz

      5/15/25 4:01:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sukhtian Ghiath M. was granted 4,285,714 shares (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      5/28/25 5:20:21 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Director Sukhtian Ghiath M. exercised 3,458,571 shares at a strike of $2.51 (SEC Form 4)

      4/A - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      3/12/25 8:56:07 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sukhtian Faisal Ghiath

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      2/6/25 4:40:17 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care